Call Us Contact Us
+44 1494 818 000     Online Enquiry
Lines open
Monday to Thursday
08:30 to 18:00
Friday
08:30 to 17:30
Pharmaceutical | Medical Devices | Scientific | Consumer Healthcare | Dental | Animal Health | FMCG | Executive
         
Latest Jobs

South West
24 May 2013 17:14



North East London
24 May 2013 16:39



South and South West
24 May 2013 16:16


Have you registered?
Once you register you can see additional job details, save jobs, track your applications and manage e-lert preferences.

Register now
Joe Moore
Operations Director
joe@zenopa.com
+44 1494 818011

Testimonials
I would highly recommend the service of Zenopa. It remained very professional throughout and aided me in getting my current position with Covidien.
Gareth, 2011

Randox introduces new drugs of abuse test

31 January 2008 00:00 in Scientific


Randox Laboratories has released a second biochip for drugs of abuse DoA urine screening.

It claims that the new DoA Array II simultaneously tests for ten drugs in a single procedure, using only one sample.

The biochip is also able to screen for six opoid analgesics including Fentanyl, Ketamine, LSD, Methaqualone and Ecstasy.

The DoA Array II's introduction follows the success of its predecessor, the DoA Array I test for Barbiturates, Amphetamines, Cocaine, Opiates and Cannaboids.

It incorporates a charge-coupled device camera which detects the chemiluminescent signal generated by each test region and advanced image-processing software which reads all ten test results simultaneously.

Both arrays can also include an eleventh test, creatinine, designed to identify adulterate urine samples.

According to Randox, the DoA screening procedure offers a "rapid consistent and cost-effective" method of testing for drugs of abuse.

The international diagnostics company is currently developing blood and oral fluid biochips to be used in drugs testing, as currently both arrays are only available for urine screening.
ADNFCR-1050-ID-18448310-ADNFCR

Other news stories from 31/01/2008

Recent news

Read more in the Zenopa News Archive

How this news is generated

Story collated for Zenopa by the Adfero News Agency



   
© Copyright 2013 Zenopa Ltd